{"id":986886,"date":"2026-07-29T20:01:59","date_gmt":"2026-07-30T00:01:59","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/johnson-johnson-completes-acquisition-of-firefly-bio-inc-to-advance-next-generation-oncology-innovation\/"},"modified":"2026-07-29T20:01:59","modified_gmt":"2026-07-30T00:01:59","slug":"johnson-johnson-completes-acquisition-of-firefly-bio-inc-to-advance-next-generation-oncology-innovation","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/johnson-johnson-completes-acquisition-of-firefly-bio-inc-to-advance-next-generation-oncology-innovation\/","title":{"rendered":"Johnson &amp; Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation"},"content":{"rendered":"<p>        <!--.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p>\nJohnson &amp; Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation<\/p>\n<ul class=\"bwlistdisc\">\n<li><i>Broadens capabilities in targeting pan-KRAS and other drivers of hard-to-treat cancers<\/i><\/li>\n<li><i>Adds novel degrader antibody conjugate platform designed to address key limitations of existing therapies<\/i><\/li>\n<li><i>Advances leadership in next-generation antibody engineering to accelerate oncology innovation<\/i><\/li>\n<\/ul>\n<p>NEW BRUNSWICK, N.J.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nJohnson &amp; Johnson (NYSE: JNJ) today announced the successful completion of its acquisition of Firefly Bio, Inc., a biotechnology company advancing its proprietary Firelink\u2122 degrader antibody conjugate (DAC) platform, for $1 billion in cash. The Firelink\u2122 DAC platform expands Johnson &amp; Johnson\u2019s oncology portfolio and advances its ambition to develop targeted therapies for some of the most prevalent and difficult-to-treat solid tumors, including KRAS-driven cancers, where patients continue to face significant unmet need<sup>1<\/sup>.<\/p>\n<p>\nWith the close of the transaction, Johnson &amp; Johnson further deepens its capabilities in next-generation antibody engineering and broadens its strategy for tackling complex tumor biology. The Firelink\u2122 DAC platform is designed to deliver highly selective protein degraders directly to cancer cells, enabling targeted activity while preserving healthy tissue\u2014a key limitation of many current treatment approaches.<\/p>\n<p>\n\u201cThe completion of this acquisition marks an important step in advancing new approaches to better address difficult-to-treat solid tumors,\u201d said John Reed, M.D., Ph.D., Executive Vice President, Innovative Medicine, Research &amp; Development, Johnson &amp; Johnson. \u201cBy bringing together Firefly Bio\u2019s differentiated technology with our deep expertise in oncology and antibody engineering, we are well positioned to accelerate the development of more precise and effective therapies. We are excited to welcome the talented Firefly Bio team to Johnson &amp; Johnson as we continue this work together.\u201d<\/p>\n<p><b>Johnson &amp; Johnson is at the forefront of oncology therapies<\/b><\/p>\n<p>\nAnchored in decades of oncology leadership, Johnson &amp; Johnson is redefining standards of care and expanding what is possible for people living with cancer. Integrating Firefly Bio\u2019s capabilities further strengthens this commitment, enabling new approaches to address some of the most challenging solid tumors, including those driven by KRAS.<\/p>\n<p><b>About the agreement<\/b><\/p>\n<p>\nThe transaction will be accounted for as an asset acquisition, resulting in an in-process research and development charge of approximately $1 billion in the third quarter of 2026. Johnson &amp; Johnson expects the transaction to dilute adjusted operational earnings per share and adjusted earnings per share by approximately $0.46 in 2026 and approximately $0.08 in 2027. Please refer to the Current Report on Form 8-K furnished to the SEC on the date of this press release for updated full year 2026 guidance.<\/p>\n<p><b>About Johnson &amp; Johnson<\/b><\/p>\n<p>\nAt Johnson &amp; Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity.<\/p>\n<p>\nLearn more at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.jnj.com%2F&amp;esheet=54579653&amp;newsitemid=20260729714290&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.jnj.com%2F&amp;index=1&amp;md5=b783b5840638b23c5ff704c7e3289cd9\">https:\/\/www.jnj.com\/<\/a> or at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.innovativemedicine.jnj.com&amp;esheet=54579653&amp;newsitemid=20260729714290&amp;lan=en-US&amp;anchor=www.innovativemedicine.jnj.com&amp;index=2&amp;md5=b9383020fd03f5e50c9fb548619d5eac\">www.innovativemedicine.jnj.com<\/a>. Follow us @JNJInnovMed.<\/p>\n<p><b>Caution Concerning Forward-Looking Statements<\/b>:<\/p>\n<p>\nThis press release contains \u201cforward-looking statements\u201d as defined in the Private Securities Litigation Reform Act of 1995 regarding the acquisition of Firefly Bio, Inc. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson &amp; Johnson. Risks and uncertainties include, but are not limited to: the potential that the expected benefits and opportunities of the acquisition may not be realized or may take longer to realize than expected; challenges inherent in product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new products; economic conditions, including currency exchange and interest rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes to applicable laws and regulations, including tax laws and global health care reforms; adverse litigation or government action; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; and trends toward health care cost containment. In addition, there will be risks and uncertainties related to the ability of the Johnson &amp; Johnson family of companies to successfully integrate Firefly Bio, Inc. as well as the ability to ensure successful development and regulatory approval of Firefly Bio, Inc. programs. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson &amp; Johnson\u2019s most recent Annual Report on Form 10-K, including in the sections captioned \u201cCautionary Note Regarding Forward-Looking Statements\u201d and \u201cItem 1A. Risk Factors,\u201d and in Johnson &amp; Johnson\u2019s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=54579653&amp;newsitemid=20260729714290&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=3&amp;md5=781ff6633651de0302fdd82b347a6d2d\">www.sec.gov<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.jnj.com&amp;esheet=54579653&amp;newsitemid=20260729714290&amp;lan=en-US&amp;anchor=www.jnj.com&amp;index=4&amp;md5=e921eab83f32d68972f6a65bce08f47c\">www.jnj.com<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.investor.jnj.com&amp;esheet=54579653&amp;newsitemid=20260729714290&amp;lan=en-US&amp;anchor=www.investor.jnj.com&amp;index=5&amp;md5=643b06613c4926786e6529b135492c7b\">www.investor.jnj.com<\/a> or on request from Johnson &amp; Johnson. Johnson &amp; Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.<\/p>\n<p><b>Non-GAAP Financial Measures<\/b><\/p>\n<p>\nThis press release includes adjusted operational earnings per share and adjusted earnings per share, which represent non-GAAP financial measures. Johnson &amp; Johnson believes that providing these non-GAAP financial measures enhance the company\u2019s and investors\u2019 understanding of our financial performance. Non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures determined or calculated in accordance with GAAP. The company\u2019s definitions of its non-GAAP financial measures may not be comparable to similarly titled measures reported by other companies. The most directly comparable GAAP measure to adjusted operational earnings per share and adjusted earnings per share is earnings per share, or EPS. The Company is not providing reconciliations to EPS, however, because Johnson &amp; Johnson does not provide GAAP financial measures on a forward-looking basis as the company is unable to predict with reasonable certainty the ultimate outcome of adjusted items, such as legal proceedings, unusual gains and losses, acquisition-related expenses, and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson &amp; Johnson\u2019s results computed in accordance with GAAP.<\/p>\n<p><sup>1<\/sup><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.sciencedirect.com%2Fscience%2Farticle%2Fpii%2FS1535610826000103%23bib19&amp;esheet=54579653&amp;newsitemid=20260729714290&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.sciencedirect.com%2Fscience%2Farticle%2Fpii%2FS1535610826000103%23bib19&amp;index=6&amp;md5=b0dab56f0152ace5012e00eb3e9ea6ca\">https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1535610826000103#bib19<\/a><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260729714290r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260729714290\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260729714290\/en\/<\/a><\/span><\/p>\n<p><b>Media contact:<br \/>\n<\/b><br \/>J&amp;J Global Media Relations<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:Media-relations@its.jnj.com\">Media-relations@its.jnj.com<\/a><\/p>\n<p><b>Investor contact:<br \/>\n<\/b><br \/>Jess Margevich<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:investor-relations@its.jnj.com\">investor-relations@its.jnj.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> New Jersey United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260729714290\/en\/1889501\/3\/JNJ_Logo_SingleLine_Red_RGB.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Johnson &amp; Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation Broadens capabilities in targeting pan-KRAS and other drivers of hard-to-treat cancers Adds novel degrader antibody conjugate platform designed to address key limitations of existing therapies Advances leadership in next-generation antibody engineering to accelerate oncology innovation NEW BRUNSWICK, N.J.&#8211;(BUSINESS WIRE)&#8211; Johnson &amp; Johnson (NYSE: JNJ) today announced the successful completion of its acquisition of Firefly Bio, Inc., a biotechnology company advancing its proprietary Firelink\u2122 degrader antibody conjugate (DAC) platform, for $1 billion in cash. The Firelink\u2122 DAC platform expands Johnson &amp; Johnson\u2019s oncology portfolio and advances its ambition to develop targeted therapies for some of the most prevalent and difficult-to-treat solid tumors, including KRAS-driven cancers, where patients &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/johnson-johnson-completes-acquisition-of-firefly-bio-inc-to-advance-next-generation-oncology-innovation\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Johnson &amp; Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-986886","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Johnson &amp; Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/johnson-johnson-completes-acquisition-of-firefly-bio-inc-to-advance-next-generation-oncology-innovation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Johnson &amp; Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Johnson &amp; Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation Broadens capabilities in targeting pan-KRAS and other drivers of hard-to-treat cancers Adds novel degrader antibody conjugate platform designed to address key limitations of existing therapies Advances leadership in next-generation antibody engineering to accelerate oncology innovation NEW BRUNSWICK, N.J.&#8211;(BUSINESS WIRE)&#8211; Johnson &amp; Johnson (NYSE: JNJ) today announced the successful completion of its acquisition of Firefly Bio, Inc., a biotechnology company advancing its proprietary Firelink\u2122 degrader antibody conjugate (DAC) platform, for $1 billion in cash. The Firelink\u2122 DAC platform expands Johnson &amp; Johnson\u2019s oncology portfolio and advances its ambition to develop targeted therapies for some of the most prevalent and difficult-to-treat solid tumors, including KRAS-driven cancers, where patients &hellip; Continue reading &quot;Johnson &amp; Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/johnson-johnson-completes-acquisition-of-firefly-bio-inc-to-advance-next-generation-oncology-innovation\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-30T00:01:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260729714290r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/johnson-johnson-completes-acquisition-of-firefly-bio-inc-to-advance-next-generation-oncology-innovation\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/johnson-johnson-completes-acquisition-of-firefly-bio-inc-to-advance-next-generation-oncology-innovation\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Johnson &amp; Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation\",\"datePublished\":\"2026-07-30T00:01:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/johnson-johnson-completes-acquisition-of-firefly-bio-inc-to-advance-next-generation-oncology-innovation\\\/\"},\"wordCount\":1116,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/johnson-johnson-completes-acquisition-of-firefly-bio-inc-to-advance-next-generation-oncology-innovation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260729714290r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/johnson-johnson-completes-acquisition-of-firefly-bio-inc-to-advance-next-generation-oncology-innovation\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/johnson-johnson-completes-acquisition-of-firefly-bio-inc-to-advance-next-generation-oncology-innovation\\\/\",\"name\":\"Johnson &amp; Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/johnson-johnson-completes-acquisition-of-firefly-bio-inc-to-advance-next-generation-oncology-innovation\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/johnson-johnson-completes-acquisition-of-firefly-bio-inc-to-advance-next-generation-oncology-innovation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260729714290r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-07-30T00:01:59+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/johnson-johnson-completes-acquisition-of-firefly-bio-inc-to-advance-next-generation-oncology-innovation\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/johnson-johnson-completes-acquisition-of-firefly-bio-inc-to-advance-next-generation-oncology-innovation\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/johnson-johnson-completes-acquisition-of-firefly-bio-inc-to-advance-next-generation-oncology-innovation\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260729714290r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260729714290r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/johnson-johnson-completes-acquisition-of-firefly-bio-inc-to-advance-next-generation-oncology-innovation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Johnson &amp; Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Johnson &amp; Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/johnson-johnson-completes-acquisition-of-firefly-bio-inc-to-advance-next-generation-oncology-innovation\/","og_locale":"en_US","og_type":"article","og_title":"Johnson &amp; Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation - Market Newsdesk","og_description":"Johnson &amp; Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation Broadens capabilities in targeting pan-KRAS and other drivers of hard-to-treat cancers Adds novel degrader antibody conjugate platform designed to address key limitations of existing therapies Advances leadership in next-generation antibody engineering to accelerate oncology innovation NEW BRUNSWICK, N.J.&#8211;(BUSINESS WIRE)&#8211; Johnson &amp; Johnson (NYSE: JNJ) today announced the successful completion of its acquisition of Firefly Bio, Inc., a biotechnology company advancing its proprietary Firelink\u2122 degrader antibody conjugate (DAC) platform, for $1 billion in cash. The Firelink\u2122 DAC platform expands Johnson &amp; Johnson\u2019s oncology portfolio and advances its ambition to develop targeted therapies for some of the most prevalent and difficult-to-treat solid tumors, including KRAS-driven cancers, where patients &hellip; Continue reading \"Johnson &amp; Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/johnson-johnson-completes-acquisition-of-firefly-bio-inc-to-advance-next-generation-oncology-innovation\/","og_site_name":"Market Newsdesk","article_published_time":"2026-07-30T00:01:59+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260729714290r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/johnson-johnson-completes-acquisition-of-firefly-bio-inc-to-advance-next-generation-oncology-innovation\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/johnson-johnson-completes-acquisition-of-firefly-bio-inc-to-advance-next-generation-oncology-innovation\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Johnson &amp; Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation","datePublished":"2026-07-30T00:01:59+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/johnson-johnson-completes-acquisition-of-firefly-bio-inc-to-advance-next-generation-oncology-innovation\/"},"wordCount":1116,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/johnson-johnson-completes-acquisition-of-firefly-bio-inc-to-advance-next-generation-oncology-innovation\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260729714290r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/johnson-johnson-completes-acquisition-of-firefly-bio-inc-to-advance-next-generation-oncology-innovation\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/johnson-johnson-completes-acquisition-of-firefly-bio-inc-to-advance-next-generation-oncology-innovation\/","name":"Johnson &amp; Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/johnson-johnson-completes-acquisition-of-firefly-bio-inc-to-advance-next-generation-oncology-innovation\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/johnson-johnson-completes-acquisition-of-firefly-bio-inc-to-advance-next-generation-oncology-innovation\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260729714290r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-07-30T00:01:59+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/johnson-johnson-completes-acquisition-of-firefly-bio-inc-to-advance-next-generation-oncology-innovation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/johnson-johnson-completes-acquisition-of-firefly-bio-inc-to-advance-next-generation-oncology-innovation\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/johnson-johnson-completes-acquisition-of-firefly-bio-inc-to-advance-next-generation-oncology-innovation\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260729714290r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260729714290r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/johnson-johnson-completes-acquisition-of-firefly-bio-inc-to-advance-next-generation-oncology-innovation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Johnson &amp; Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/986886","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=986886"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/986886\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=986886"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=986886"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=986886"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}